These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32599030)

  • 1. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
    Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
    Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma.
    Bergman D; Modh A; Schultz L; Snyder J; Mikkelsen T; Shah M; Ryu S; Siddiqui MS; Walbert T
    J Neurooncol; 2020 Jun; 148(2):353-361. PubMed ID: 32444980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-irradiation treatment regimens for patients with recurrent glioma - Evaluation of the optimal dose and best concurrent therapy.
    Fleischmann DF; Gajdi L; Corradini S; Schönecker S; Marschner S; Bodensohn R; Hofmaier J; Garny S; Forbrig R; Thon N; Belka C; Niyazi M
    Radiother Oncol; 2024 Oct; 199():110437. PubMed ID: 39013502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
    Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
    J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
    J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
    Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
    Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
    Levin VA; Chan J; Datta M; Yee JL; Jain RK
    J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with ("pseudo-randomized") treatment allocation by the health insurance provider.
    Hofmann S; Schmidt MA; Weissmann T; Eyüpoglu I; Strnad A; Semrau S; Fietkau R; Putz F; Lettmaier S
    J Neurooncol; 2020 Jun; 148(2):373-379. PubMed ID: 32409944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
    Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
    Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensity modulated radiation therapy with pulsed reduced dose rate as a reirradiation strategy for recurrent central nervous system tumors: An institutional series and literature review.
    Murphy ES; Rogacki K; Godley A; Qi P; Reddy CA; Ahluwalia MS; Peereboom DM; Stevens GH; Yu JS; Kotecha R; Suh JH; Chao ST
    Pract Radiat Oncol; 2017; 7(6):e391-e399. PubMed ID: 28666902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
    Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
    J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
    Chen Y; Guo L; Li X; Liu R; Ren C; Du S
    Clin Neurol Neurosurg; 2020 Nov; 198():106239. PubMed ID: 33007724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
    Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
    Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.
    Lyu Y; Liu S; You H; Hou B; Wang Y; Ma W; Feng F
    J Magn Reson Imaging; 2017 Aug; 46(2):565-573. PubMed ID: 27902863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.